SLC38A3, another transporter of Gln, activates the PDK1/AKT signaling pathway and promotes the metastasis of NSCLC by regulating the transport of Gln and histidine, indicating that SLC38A3 owns consistent therapeutic potential for the treatment of NSCLC (43). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.